24 results
DEFA14A
CYT
Cyteir Therapeutics Inc
30 Jun 23
Additional proxy soliciting materials
10:37am
could potentially benefit from treatment with CYT-0851, and the current financial and regulatory environment, continuation of development of CYT-0851 … ; and the uncertain macroeconomic environment. These statements are also subject to a number of material risks and uncertainties that are described in Cyteir’s
8-K
EX-99.1
CYT
Cyteir Therapeutics Inc
30 Jun 23
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution
10:22am
predictive biomarkers to identify who could potentially benefit from treatment with CYT-0851, and the current financial and regulatory environment … after shareholder approval; and the uncertain macroeconomic environment. These statements are also subject to a number of material risks
S-3
kctz2slbqybu984
8 Aug 22
Shelf registration
5:29pm
S-3
EX-1.2
5dfr2occzem
8 Aug 22
Shelf registration
5:29pm
8-K
EX-99.1
1qeulrg9jyq7s2lxyqth
26 Apr 22
Regulation FD Disclosure
8:37am
10-K
82fs8vq5 sb
16 Mar 22
Annual report
4:08pm
10-Q
c6dsu
9 Aug 21
Quarterly report
4:28pm
424B4
irfmr888l77j4renwmw
21 Jun 21
Prospectus supplement with pricing info
6:13am
S-1/A
EX-1.1
kpznxlmdzy
4 Jun 21
IPO registration (amended)
4:32pm
S-1/A
9eiu6m6z gj422l
4 Jun 21
IPO registration (amended)
4:32pm
S-1
EX-10.1
0hzquan
28 May 21
IPO registration
4:01pm
S-1
86adlz lbrdru3
28 May 21
IPO registration
4:01pm